Celgene Corporation

Celgene — Merger or Acquisition (March 2019)

25 slides from Celgene's merger presentation, Mar 25, 2019

  1. Slide 1: Significant Value Creation Opportunity from Celgene Pipeline

    Significant Value Creation Opportunity from Celgene Pipeline INVESTOR PRESENTATIONMARCH 25, 2019

  2. Slide 2: Important Information For Investors And Stockholders

    Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securiti

  3. Slide 3: Cautionary Statement Regarding Forward-Looking Statements

    Cautionary Statement Regarding Forward-Looking StatementsThis communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking

  4. Slide 4: Celgene's Pipeline Expected to Create Significant Value

    Celgene’s Pipeline Expected to Create Significant Value More than 80% of transaction cost supported by value of currently marketed products and synergiesValue of currently marketed products reflects more conservative assumptions than Street analyst consensus, primarily driven by RevlimidSignificant

  5. Slide 5: BMS Recognized for Industry-Leading Commercial Capabilities

    Bristol-Myers Squibb is recognized as having industry-leading commercial capabilities: Launch Execution  Efficient & Effective Commercialization Model  World-Class Access & Reimbursement  Innovating to Transform MarketsCommercial execution has resulted in exceptional product performance:Almost 6

  6. Slide 6: Celgene Near-term Pipeline is a Substantially De-risked, Pre-launch Portfolio

    Celgene Near-term Pipeline is a Substantially De-risked, Pre-launch Portfolio with Significant Potential to Generate Value Asset Registrational Profile FDA & Approval Status Ozanimod Successful Phase 3 in Multiple Sclerosis Submitted in EU, US by 1Q2019 Luspatercept Successful Phase 3 in 2L Myelodys

  7. Slide 7: BMS Has World-Class Commercial Capabilities to Accelerate Near-Term Launches

    BMS Has World-Class Commercial Capabilities to Accelerate Near-Term Launches Flawlessly launched 16 Opdivo indications in 4 yearsLeading I-O share where Opdivo is approved Established Eliquis as the #1 new oral anticoagulant despite entering market 3rd Transformed our portfolio over a 5-year period

  8. Slide 8: Proven Success in Transitioning Portfolio Over Time

    Proven Success in Transitioning Portfolio Over Time BMS Historical Total Sales ($Bn) Contribution of Sales (%) +$14Bn Established Brands Other Prioritized Brands Prioritized Brands Launched Since 2011 Other +$2Bn ($9Bn) +$6Bn Management has a proven track record of success in transitioning a mature

  9. Slide 9: Opdivo is the Most Successful Oncology Launch

    Opdivo is the Most Successful Oncology Launch Top Oncology Products: Cumulative Sales in 4 Years Post Launch US Sales ($Bn) Approvals Post-Launch 0 2 4 6 8 10 Opdivo Avastin Taxotere 12 14 16 in Yearsin the U.S. Approvals 16 4 Source: IQVIA NSP $ Sales US only

  10. Slide 10: Opdivo's Future Growth Potential

    Opdivo’s Future Growth Potential is Driven By:Broadened first line lung cancer programMultiple registered trials in various tumor typesIndustry leading development program in the adjuvant setting Lung 2L Leadership with 28% BMS I-O share3L+ SCLC Leadership with 68% BMS I-O share Melanoma 1L Leadersh

  11. Slide 11: Eliquis Annual Sales and Market Share

    Eliquis Annual Sales $Bn; 2013 - 2018 5 Year CAGR: +113% +430% +140% +80% +46% +32% Annual Growth: #1 NOAC(Mar’15) #1 OAC(Feb’16) Evolution of OAC Market Share in Atrial Fibrillation (AF)1 January 2013 – September 2018 Chart represents New-to-Brand (Naïve+Switch) Rxs (NBRx). Eliquis, Xarelto, Pradax

  12. Slide 12: Ozanimod has a Proven and Differentiated Profile

    Ozanimod has a Proven and Differentiated Profile Compelling Market Opportunity Multiple Sclerosis (MS): Very large market with potential for increased use of oral medicinesWorldwide sales in 2018 of ~$23B with oral therapies comprising 45% of the marketInflammatory Bowel Disease (IBD): Substantial u

  13. Slide 13: Ozanimod Strong Efficacy and Safety Profile in Phase 3 Trials

    Source: FDA labels, clinicaltrials.gov Note: Cross Trial ComparisonAvonex ARR from Ozanimod Phase 3 clinical trial, Rebif ARR from Ocrevus Phase 3 clinical trialAnnualized relapse rate (ARR) Oral IV Subcutaneous / intramuscular1 Ozanimod has Demonstrated a Strong Efficacy Profile and Potentially Bes

  14. Slide 14: Luspatercept Addresses Important Unmet Needs

    Luspatercept Addresses Important Unmet Needs Compelling Market Opportunity Large underserved patient population living with chronic anemiaRoughly 90K patients living with low-intermediate risk Myelodysplastic Syndrome in U.S. and EU5Only treatment options are ESAs (approximately two-thirds of patien

  15. Slide 15: Luspatercept Positive Phase 3 Data in Myelodysplastic Syndromes

    Luspatercept is a First-in-Class Anemia Treatment with Positive Phase 3 Data in Myelodysplastic Syndromes Source: ClinicalTrials.gov, Fenaux et al., ASH (2018), Platzbecker et al., Lancet Oncology (2017), Bajar et al., Blood (2014), Celgene websiteNotes: 1. mHI-E (modified erythroid response): defin

  16. Slide 16: Liso-cel Differentiated for Efficacy and Safety in Lymphomas

    Liso-cel Profile Emerging as Differentiated for Both Efficacy and Safety in Lymphomas Compelling Market Opportunity Initially targeting the most common form of the most prevalent blood cancerRoughly 22K patients in the U.S. and EU5 are treated for Diffuse Large B-Cell Lymphoma* having failed the sta

  17. Slide 17: Liso-cel Strong Efficacy Profile with Improved Complete Response Rates

    Liso-cel has a Strong Efficacy Profile with Significantly Improved Complete Response Rates Relative to Standard of Care EFFICACYResponse Rate at 6 months SAFETYCytokine Release Syndrome ™ ™ ™ ™ Neurotoxicity ™ ™ U.S. submission expected 2H2019 Data presented to show potential profile of Liso-cel, wh

  18. Slide 18: bb2121 is a First-in-Class Agent for Multiple Myeloma

    bb2121 is a First-in-Class agent for Multiple Myeloma Compelling Market Opportunity Multiple Myeloma expected to reach ~$25B+ in sales by 2022Roughly 47K patients have failed two or more prior treatmentsFor patients who have failed the standard initial treatments, existing medicines have limited eff

  19. Slide 19: bb2121 Demonstrated 50% Complete Response Rate in Multiple Myeloma

    bb2121 Demonstrated Transformational Efficacy, with 50% Complete Response Rate in Multiple Myeloma U.S. submission expected in late 2019/early 2020 Standard Treatment Regimens Across Multiple Myeloma (%) Emerging bb2121 Profile ORR 69%-82% ORR 59%-91% ORR 29% - 59% ORR 96% N= 22 Complete Response PR

  20. Slide 20: Fedratinib First-in-Class Therapy Under FDA Review

    Fedratinib is a First-in-Class Therapy, Under FDA Review for Patients Resistant/Refractory to Jakafi Compelling Market Opportunity First and only option for patients with Myelofibrosis that fail or are intolerant to JakafiJakafi is the only approved option in Myelofibrosis with sales estimated to re

  21. Slide 21: High Unmet Medical Need in MF Patients Failing Jakafi

    High unmet medical need in MF patients that fail or cannot tolerate Jakafi EFFICACY (JAKARTA2 Trial) 55% of patients achieved splenic volume reduction of ≥35% compared to baseline at week 24 26% of patients achieved total symptom score ≥50% compared to baseline at week 24 Fedratinib: selective JAK2

  22. Slide 22: Early Pipeline and Platforms Support Long-Term Outlook

    Early Pipeline and Platforms Support Long-Term Outlook Through Continuous Innovation Long-term revenue outlook in biopharma is driven by bringing innovative new medicines to patients, which is costly, high-risk, and has long timelinesSustained pipeline success requires:strong leadershiphigh quality

  23. Slide 23: Significant Optionality in Celgene Early Stage Pipeline and Platforms

    Significant Optionality in Celgene Early Stage Pipeline and New Technology Platforms Transaction provides BMS with an additional >20 Phase 1 and 2 programs, and >30 defined preclinical programsNew capabilities in cell therapy and protein homeostasisStrongest position in BCMA: 5 programs total, first

  24. Slide 24: BMS in 2025: Positioned for Continued Leadership

    BMS in 2025: Positioned for Continued Leadership CHEMISTRY BIOLOGICS CELL THERAPY Underpinned by cutting edgetechnologies and discovery platforms With access to additional modality platforms through strong external partnerships PATIENT-CENTRIC INNOVATION Broad, Balanced & Earlier Life-Cycle Marketed

  25. Slide 25: Vote "FOR" the transaction with Celgene today

    Vote “FOR” the transaction with Celgene today by following the instructions on your proxy card and voting “FOR” each of the proposals listed on the WHITE proxy card REMEMBER: Vote only on the WHITE proxy card — discard any blue proxy cards you receive from Starboard If you have questions or need ass

Celgene — Merger or Acquisition (March 2019) on 6ix